Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Paavo Pietarinen"'
Autor:
Anna Anttalainen, Paavo Pietarinen, Samuli Tuominen, Riikka Mattila, Aino Mutka, Aija Knuuttila
Publikováno v:
Current Oncology, Vol 31, Iss 5, Pp 2700-2712 (2024)
While KRAS is the most frequently mutated oncogene in non-small cell lung cancer (NSCLC), KRAS-mutant tumors have long been considered difficult to treat and thus, an unmet need still remains. Partly due to the lack of targeted treatments, comprehens
Externí odkaz:
https://doaj.org/article/56ddc47320eb40d78a3c2a1289f1e57f
Autor:
Olli Dufva, Matti Kankainen, Tiina Kelkka, Nodoka Sekiguchi, Shady Adnan Awad, Samuli Eldfors, Bhagwan Yadav, Heikki Kuusanmäki, Disha Malani, Emma I Andersson, Paavo Pietarinen, Leena Saikko, Panu E. Kovanen, Teija Ojala, Dean A. Lee, Thomas P. Loughran, Hideyuki Nakazawa, Junji Suzumiya, Ritsuro Suzuki, Young Hyeh Ko, Won Seog Kim, Shih-Sung Chuang, Tero Aittokallio, Wing C. Chan, Koichi Ohshima, Fumihiro Ishida, Satu Mustjoki
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-12 (2018)
Aggressive natural killer-cell leukemia (ANKL) has few targeted therapies. Here ANKL patients are reported to harbor STAT3, RAS-MAPK pathway, DDX3X and epigenetic modifier mutations; and drug sensitivity profiling uncovers the importance of the JAK-S
Externí odkaz:
https://doaj.org/article/a90516e221ea4f0c9791e1e130cc3ead
Autor:
Shady Adnan Awad, Olli Dufva, Jay Klievink, Ella Karjalainen, Aleksandr Ianevski, Paavo Pietarinen, Daehong Kim, Swapnil Potdar, Maija Wolf, Kourosh Lotfi, Tero Aittokallio, Krister Wennerberg, Kimmo Porkka, Satu Mustjoki
Publikováno v:
Blood. 140:799-800
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1d05c2d8b87ef306cb3874752e4e55bf
https://doi.org/10.1182/blood-2022-165247
https://doi.org/10.1182/blood-2022-165247
Autor:
Satu Mustjoki, Bhagwan Yadav, Young Hyeh Ko, Samuli Eldfors, Emma I. Andersson, Koichi Ohshima, Panu E. Kovanen, Disha Malani, Olli Dufva, Hideyuki Nakazawa, Paavo Pietarinen, Nodoka Sekiguchi, Leena Saikko, Junji Suzumiya, Thomas P. Loughran, Matti Kankainen, Ritsuro Suzuki, Dean A. Lee, Wing C. Chan, Heikki Kuusanmäki, Shih-Sung Chuang, Teija Ojala, Shady Adnan Awad, Fumihiro Ishida, Won Seog Kim, Tiina Kelkka, Tero Aittokallio
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-12 (2018)
Nature Communications
Nature Communications
Aggressive natural killer-cell (NK-cell) leukemia (ANKL) is an extremely aggressive malignancy with dismal prognosis and lack of targeted therapies. Here, we elucidate the molecular pathogenesis of ANKL using a combination of genomic and drug sensiti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ebbd4a5bdf7fb8304c0caf1f86741a8b
https://doaj.org/article/a90516e221ea4f0c9791e1e130cc3ead
https://doaj.org/article/a90516e221ea4f0c9791e1e130cc3ead
Autor:
Pekka Ellonen, Dorine Bellanger, Jing Tang, Bhagwan Yadav, Emma I. Andersson, J P Mpindi, Olli Dufva, Samuli Eldfors, Wei Ding, Katarzyna Tomska, Marc-Henri Stern, Tea Pemovska, Carlos Cuesta-Mateos, Anneli Lauhio, Henan Zhang, Satu Mustjoki, T H Brümmendorf, Krister Wennerberg, Steffen Koschmieder, Giuliano Crispatzu, Alexandra Schrader, Soili Kytölä, Shady Adnan-Awad, Leopold Sellner, Marco Herling, Edgar Faber, Olli Kallioniemi, Małgorzata Oleś, S. Pützer, Sofia Khan, Sonja Lagström, Liye He, Timo Siitonen, Eeva-Riitta Savolainen, Paavo Pietarinen, Simon Anders, Tero Aittokallio, Wolfgang Huber, Thorsten Zenz
Publikováno v:
Leukemia
T-cell prolymphocytic leukemia (T-PLL) is a rare and aggressive neoplasm of mature T-cells with an urgent need for rationally designed therapies to address its notoriously chemo-refractory behavior. The median survival of T-PLL patients is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3bde8ff2001b74cd18697cec62357f9
Autor:
Emma I. Andersson, Christopher A. Eide, Brian J. Druker, Tea Pemovska, Satu Mustjoki, Olli Kallioniemi, Kimmo Porkka, Swapnil Potdar, Caroline A. Heckman, Paavo Pietarinen, Jorrit M. Enserink, Henrik Hjorth-Hansen, Heikki Kuusanmäki, Mika Kontro, J P Mpindi, Krister Wennerberg, Pilar Ayuda-Durán, Jeffrey W. Tyner
Publikováno v:
22606-22615
OncoTarget
Oncotarget
OncoTarget
Oncotarget
// Paavo O. Pietarinen 1 , Christopher A. Eide 2, 3 , Pilar Ayuda-Duran 4 , Swapnil Potdar 5 , Heikki Kuusanmaki 5 , Emma I. Andersson 1 , John P. Mpindi 5 , Tea Pemovska 5, 6 , Mika Kontro 1 , Caroline A. Heckman 5 , Olli Kallioniemi 5 , Krister Wen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bece82d73c36b50e127136d2aaaee06d
https://hdl.handle.net/11250/2779863
https://hdl.handle.net/11250/2779863
Autor:
L-M Aaltonen, Saku T. Sinkkonen, Leif Bäck, Johanna Ruohoalho, Paavo Pietarinen, Antti Mäkitie
Publikováno v:
Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-LaryngologyCervico-Facial Surgery. 42(2)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::448ff2bdf23fba60e50149128a0406a1
https://pubmed.ncbi.nlm.nih.gov/26865418
https://pubmed.ncbi.nlm.nih.gov/26865418
Publikováno v:
Basicclinical pharmacologytoxicology. 119(3)
CYP2D6 participates in the biotransformation of many commonly used drugs. Large genetic variability in CYP2D6 results in a wide interindividual variability in the response to CYP2D6 substrate drugs. Previous studies have assessed the phenotype and ge
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07e8ae0a17d93f83039f71aafe0946cf
https://pubmed.ncbi.nlm.nih.gov/27038154
https://pubmed.ncbi.nlm.nih.gov/27038154
Autor:
Satu Mustjoki, Young Hyeh Ko, Shady Adnan Awad, Heikki Kuusanmäki, Shih-Sung Chuang, Fumihiro Ishida, Wing C. Chan, Leena Saikko, Tiina Kelkka, Junji Suzumiya, Nodoka Sekiguchi, Won Seog Kim, Disha Malani, Paavo Pietarinen, Thomas P. Loughran, Emma I. Andersson, Olli Dufva, Samuli Eldfors, Koichi Ohshima, Panu E. Kovanen
Publikováno v:
Blood. 126:700-700
Background Natural killer (NK) cell malignancies are rare lymphoid neoplasms characterized by aggressive clinical behavior and poor treatment outcomes. Clinically they are classified as extranodal NK/T-cell lymphoma, nasal type (NKTCL) and aggressive
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2c46ec09fe8c941d58008863ab57af16
https://doi.org/10.1182/blood.v126.23.700.700
https://doi.org/10.1182/blood.v126.23.700.700
Autor:
Olli Kallioniemi, Emma I. Andersson, Mika Kontro, Muntasir Mamun Majumder, Tea Pemovska, Heikki Kuusanmäki, Perttu Koskenvesa, Bhagwan Yadav, Krister Wennerberg, Satu Mustjoki, Caroline A. Heckman, Kimmo Porkka, Paavo Pietarinen, J P Mpindi
Publikováno v:
Blood Cancer Journal
Chronic myeloid leukemia in blast crisis (CML BC) remains a challenging disease to treat despite the introduction and advances in tyrosine kinase inhibitor (TKI) therapy. In this study we set out to identify novel candidate drugs for CML BC by using
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9ed223e428ca822b26209d3ca553475
https://doi.org/10.1038/bcj.2015.30
https://doi.org/10.1038/bcj.2015.30